

Innovations in Regulatory Science Summit
Sponsored by the UCSF-Stanford Center of Excellence in Regulatory Science and Innovation

Mission Bay Conference Center, 1675 Owens St, San Francisco, CA Sunday, January 12, 2020

AGENDA

8:00 – 8:05 am	Welcome Kuldev Singh, MD, MPH - Professor of Ophthalmology at Stanford University
8:05 – 8:25 am	Overview of UCSF-Stanford CERSI Russ Altman, MD, PhD - Co-Director of UCSF-Stanford CERSI Kathy Giacomini, PhD - Co-Director of UCSF-Stanford CERSI
8:25 – 8:35 am	Opening Remarks from Stanford Marc Tessier-Lavigne, PhD - President, Stanford University
8:35 – 8:45 am	Opening Remarks from UCSF Sam Hawgood, MD - Chancellor, University of California San Francisco (UCSF)
8:45 – 8:55 am	Lightning Talk - Defining the Strength of Evidence in Therapeutic Development Steven Goodman, MD, MHS, PhD - Associate Dean of Clinical and Translational Research at Stanford
8:55 – 9:55 am Moderators: Panelists:	Panel Discussion - Accelerating Clinical Trials in the Development and Approval of Innovative Medical Products Laura Esserman, MD, MBA - Professor of Surgery at UCSF Janet Woodcock, MD - Director of Center for Drug Evaluation and Research at FDA Amy Abernethy, MD, PhD - Principal Deputy Commissioner at FDA Steven Goodman, MD, MHS, PhD - Associate Dean of Clinical and Translational Research at Stanford Sandra Horning, MD - Former Chief Medical Officer at Genentech/Roche Carl Peck, MD - Chairman of NDA Partners Alfred Sandrock, MD, PhD - Chief Medical Officer at Biogen
9:55 – 10:10 am	Break
10:10 – 10:20 am	Lightning Talk - Patient Preferences in Upper Limb Prostheses Leslie Wilson, PhD - Professor of Clinical Pharmacy at UCSF
10:20 – 11:20 am <u>Moderators</u> :	Panel Discussion - Academia, Government and Industry in Regulatory Science: Cross-Sector Collaboration and Avoiding Conflicts of Interest Howard Bauchner, MD - Editor-In-Chief of the Journal of the American Medical Association

Robert Califf, MD - Former FDA Commissioner, Head of Health Policy and Strategy,

Google Health and Verily Life Science (Alphabet)

<u>Panelists</u>: Mildred Cho, PhD - Professor of Pediatrics (Center for Biomedical Ethics) at Stanford

Arthur Ciociola, PhD - Vice President, Head Regulatory Affairs, Global Drug

Development Ophthalmology at Novartis

Malvina Eydelman, MD - Director, Office of Health Technology 1 at FDA

Carol Linden, PhD - Director, Office of Regulatory Science and Innovation at FDA Andrew Weber, MS - Accelerating Therapeutics for Opportunities in Medicine

(ATOM), GlaxoSmithKline

11:20 - 11:50 am Keynote Address

Moderator: Russ Altman, MD, PhD - Professor of Bioengineering at Stanford

<u>Speaker</u>: Janet Woodcock, MD - Director, Center for Drug Evaluation and Research at FDA

11:50 - 12:40 pm Lunch

12:40 – 12:50 pm Lightning Talk - Safer Labeling of Pediatric Medications: Reducing Literacy-

related Health Disparities among Chronically III Adolescents

Lee Sanders, MD - Associate Professor of Pediatrics at Stanford

12:50 – 1:50 pm Panel Discussion - Real-World Evidence, Artificial Intelligence and Novel Medical

Devices

Moderators: Adam Gazzaley, MD, PhD - Professor of Neurology, Physiology and Psychiatry at

UCSF

Anne Wojcicki - CEO of 23andMe

<u>Panelists</u>: Russ Altman, MD, PhD - Professor of Bioengineering at Stanford

Edward Chang, MD - Professor of Neurological Surgery at UCSF

Daphne Koller, PhD - Founder & CEO of Insitro

Curtis Langlotz, MD, PhD - Professor of Radiology at Stanford

1:50 – 2:05 pm Break

2:05 – 2:15 pm Lightning Talk - The Activity of Inactive Ingredients

Brian Shoichet, PhD - Professor of Pharmaceutical Chemistry at UCSF

2:15 – 3:15 pm Panel Discussion - Advancing Discovery to First-In-Human Clinical Trials for New

Medical Products

<u>Moderators</u>: Jay Bradner, MD - President of Novartis Institutes for Biomedical Research

Joseph Wu, MD, PhD - Director of the Stanford Cardiovascular Institute

Panelists: Hal Barron, MD - Chief Scientific Officer at GlaxoSmithKline

Mathai Mammen, MD, PhD - Global Head of Research and Development at Janssen

Peter Marks, MD, PhD - Director, Center for Biologics Evaluation and Research at

FDA

3:15 – 3:45 pm Closing Keynote

<u>Moderator</u>: George Scangos, PhD - CEO of Vir Biotechnology

<u>Speaker</u>: Peter Marks, MD, PhD – Director, Center for Biologics Evaluation and Research at

FDA

3:45 – 4:00 pm Closing Remarks

Russ Altman, MD, PhD - Co-Director of UCSF-Stanford CERSI Kathy Giacomini, PhD - Co-Director of UCSF-Stanford CERSI

4:00 – 5:00 pm Reception and Poster Session (co-sponsored by the UCSF School of Pharmacy)

Hosted by B. Joseph Guglielmo, PharmD - Dean, UCSF School of Pharmacy